Efficacy and toxicity of gefitinib in palliative treatment in recurrent squamous cell carcinoma of head and neck in poor performance elderly patients

Trial Profile

Efficacy and toxicity of gefitinib in palliative treatment in recurrent squamous cell carcinoma of head and neck in poor performance elderly patients

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top